Who founded Argonaute?

Argonaute was founded by Anthony Parker, Richard Tompkins.

Who are Argonaute's investors?

Argonaute's investors include Oxford Investment Opportunity Network (OION).

How much funding has Argonaute raised?

Argonaute has disclosed $1.8M raised across 1 round.

Where is Argonaute headquartered?

Argonaute is headquartered in Cardiff, GB.

Argonaute

Cardiff, GB · 1 known investors

Find your way into Argonaute

Paths you didn't know you had: your email and LinkedIn already hold routes to the Argonaute team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.

Biotech Deep Tech Digital Health Healthtech

Founders & leadership

Anthony Parker Co-founderCo-founder of Argonaute RNA, a UK biotech developing siRNA therapeutics for cardiovascular disease. Parker has three decades of experience in investment banking and fund management, with prior non-executive roles in biotech.

Richard TompkinsCo-founder

Mike Khan CEOHe previously served as Chief Medical Officer at Silence Therapeutics and has over 25 years of experience in preclinical, translational, and clinical drug development, including bringing siRNA candidates through IND approval and Phase 2 completion; he also held academic positions at University College London and University of Warwick and led a cardiovascular clinic at University Hospitals of Coventry and Warwickshire NHS Trust.

Board

Johnathan Vincent MatlockBoard director

David William Dawson BallBoard director

Alexander Michael FinkBoard director

Ross Thomas BurnBoard director

Nabil Hussain Muhiddin Al-ChalabyBoard director

Nigel Keith DavisBoard director

Investors · 1

Oxford Investment Opportunity Network (OION)listed by Oxford Investment Opportunity Network (OION)Oxford · $190K – $2.5M

Reported raises · per SEC filings

Form D private placements

$1.8M disclosed across 1 round · 2026

▶$1.8MraisedSep 2026 · 27 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Anthony Michael ParkerExecutive Officer, Director
Michael Mohamed Tarik KhanExecutive Officer, Director
Richard Michael TompkinsDirector
Johnathan Vincent MatlockDirector
David William Dawson BallDirector
Alexander Michael FinkDirector
Ross Thomas BurnDirector
Nabil Hussain Muhiddin Al-ChalabyDirector
Nigel Keith DavisDirector

Offering amount: $1.8M
Amount sold: $1.8M
Minimum investment: $10K
First sale: Sep 2026
Incorporated: Corporation, United Kingdom
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Argonaute do?: Argonaute RNA develops siRNA-based (RNA interference) therapeutics, with a pipeline focused on cardiovascular disease, combining oligonucleotide chemistry and drug development expertise. The UK biotech takes early-stage academic ideas through preclinical and clinical development.
Who founded Argonaute?: Argonaute was founded by Anthony Parker, Richard Tompkins.
Who are Argonaute's investors?: Argonaute's investors include Oxford Investment Opportunity Network (OION).
How much funding has Argonaute raised?: Argonaute has disclosed $1.8M raised across 1 round.
Where is Argonaute headquartered?: Argonaute is headquartered in Cardiff, GB.